M. Biglietto

541 total citations
16 papers, 209 citations indexed

About

M. Biglietto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Biglietto has authored 16 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in M. Biglietto's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Genetic factors in colorectal cancer (4 papers). M. Biglietto is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Genetic factors in colorectal cancer (4 papers). M. Biglietto collaborates with scholars based in Italy, Czechia and Germany. M. Biglietto's co-authors include Giacomo Cartenì, Evaristo Maiello, Francesco Giuliani, Matilde Lambiase, Antonio Rinaldi, Daniele Rizzi, Fortunato Ciardiello, Riziero Esposito Abate, Erika Martinelli and Nicola Normanno and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M. Biglietto

16 papers receiving 206 citations

Peers

M. Biglietto

ONCOL

PRM

PFM

Thomas Göhler Germany

Ariane Nguyen United States

Sanjeev Deva New Zealand

Chuanben Chen China

Nathalie Leclercq France

Rosa Rita Silva Italy

Umair Mahmood United States

K. P. Theall United States

Sreelakshmi Mallappa United Kingdom

Thomas Göhler Germany

M. Biglietto

132 ×1.1

ONCOL

56 ×0.7

67 ×0.8

PRM

28 ×0.5

PFM

39 ×0.8

Citations per year, relative to M. Biglietto M. Biglietto (= 1×) peers Thomas Göhler

Countries citing papers authored by M. Biglietto

Since Specialization

Citations

This map shows the geographic impact of M. Biglietto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Biglietto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Biglietto more than expected).

Fields of papers citing papers by M. Biglietto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Biglietto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Biglietto. The network helps show where M. Biglietto may publish in the future.

Co-authorship network of co-authors of M. Biglietto

This figure shows the co-authorship network connecting the top 25 collaborators of M. Biglietto. A scholar is included among the top collaborators of M. Biglietto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Biglietto. M. Biglietto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Cardarelli, Silvia, M. Biglietto, Tiziana Orsini, et al.. (2024). Modulation of cAMP/cGMP signaling as prevention of congenital heart defects in Pde2A deficient embryos: a matter of oxidative stress. Cell Death and Disease. 15(2). 169–169. 2 indexed citations

Normanno, Nicola, Riziero Esposito Abate, Matilde Lambiase, et al.. (2017). RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Annals of Oncology. 29(1). 112–118. 81 indexed citations

Maiello, Evaristo, Erika Martinelli, Claudia Cardone, et al.. (2016). Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial. Annals of Oncology. 27. iv39–iv39. 4 indexed citations

Ciardiello, Fortunato, Lisa Salvatore, Stefano Cascinu, et al.. (2015). Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study. Annals of Oncology. 26. vi37–vi37. 3 indexed citations

Lorenzo, Giuseppe Di, Carlo Buonerba, M. Biglietto, et al.. (2010). The therapy of kidney cancer with biomolecular drugs. Cancer Treatment Reviews. 36. S16–S20. 26 indexed citations

Fedele, Palma, Francesco Giuliani, M. Biglietto, et al.. (2009). Bi-weekly administration of capecitabine + oxaliplatin (Xelox-2) in first-line treatment of advanced colorectal cancer (ACRC): A phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM). Journal of Clinical Oncology. 27(15_suppl). e15066–e15066. 3 indexed citations

Cartenì, Giacomo, Antonio Maria Grimaldi, Teresa Guida, et al.. (2008). Target therapy in metastatic renal cell carcinoma. European Journal of Cancer Supplements. 6(14). 38–41. 2 indexed citations

Caponigro, Francesco, Elena Massa, Luigi Manzione, et al.. (2001). Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Annals of Oncology. 12(2). 199–202. 29 indexed citations

Comella, P., Ferdinando De Vita, Lucia Liguori, et al.. (2001). Biweekly irinotecan (IRI) with 6s-folinic acid (FA)-modulated 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC): a phase III study. European Journal of Cancer. 37. S302–S302. 1 indexed citations

10.

Comella, P., Ferdinando De Vita, S. Mancarella, et al.. (2000). Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II–III randomized trial. Annals of Oncology. 11(10). 1323–1334. 23 indexed citations

11.

Sannolo, Nicola, et al.. (1999). Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry. Journal of Mass Spectrometry. 34(8). 845–849. 16 indexed citations

12.

Caponigro, Francesco, P. Comella, Antonio Daponte, et al.. (1997). A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck. Oncology Reports. 4(6). 1207–11. 3 indexed citations

13.

Riccardi, Ferdinando, et al.. (1997). Phase II trial of paclitaxel (P) and cisplatin (COOP) in patients with advanced breast cancer refractory to anthracycline (A) therapy. European Journal of Cancer. 33. S160–S160. 1 indexed citations

14.

Tucci, A., et al.. (1991). A phase II study of octreotide in metastatic advanced prostatic cancer (MAPC). European Journal of Cancer and Clinical Oncology. 27. S88–S88. 2 indexed citations

15.

Cartenì, Giacomo, et al.. (1990). Sandostatin, a long acting somatostatin analogue, in the treatment of advanced metastatic prostatic cancer. European Journal of Cancer and Clinical Oncology. 26(2). 186–186. 6 indexed citations

16.

Cartenì, Giacomo, et al.. (1984). Lonidamine Alone and in Combination with Other Chemotherapeutic Agents in the Treatment of Cancer Patients. Oncology. 41(1). 108–112. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact